Abstract
Glioma-associated oncogenes (GLIs) are zinc finger protein family members and downstream regulatory factors of the classic Hedgehog (Hh) signaling pathway. GLI proteins influence the growth and development of organisms and aid in tissue repair. However, aberrant expression of the GLI family member GLI1 promotes carcinogenesis by inducing epithelial–mesenchymal transition (EMT), angiogenesis, and other signaling pathways. Overexpression of GLI1 is thought to be an indicator of poor prognosis as well as a potential therapeutic target for cancers. GLI inhibitors such as zerumbone, GANT61, resveratrol, and cyclopamine depress the Hh pathway in vitro and in vivo cancer research, and other non-canonical pathways may also activate expression of GLI1. Here, we summarize GLI function in carcinogenesis and cancer-targeted therapy.
Keywords: Hedgehog signaling, GLI proteins, carcinogenesis, targeted therapy, non-canonical pathways, mutation.
Current Cancer Drug Targets
Title:Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Volume: 18 Issue: 6
Author(s): Jie Wu, Dingxin Di, Chen Zhao, Yingyi Liu, Hongxia Chen, Yan Gong, Xianda Zhao and Honglei Chen*
Affiliation:
- Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan 430071,China
Keywords: Hedgehog signaling, GLI proteins, carcinogenesis, targeted therapy, non-canonical pathways, mutation.
Abstract: Glioma-associated oncogenes (GLIs) are zinc finger protein family members and downstream regulatory factors of the classic Hedgehog (Hh) signaling pathway. GLI proteins influence the growth and development of organisms and aid in tissue repair. However, aberrant expression of the GLI family member GLI1 promotes carcinogenesis by inducing epithelial–mesenchymal transition (EMT), angiogenesis, and other signaling pathways. Overexpression of GLI1 is thought to be an indicator of poor prognosis as well as a potential therapeutic target for cancers. GLI inhibitors such as zerumbone, GANT61, resveratrol, and cyclopamine depress the Hh pathway in vitro and in vivo cancer research, and other non-canonical pathways may also activate expression of GLI1. Here, we summarize GLI function in carcinogenesis and cancer-targeted therapy.
Export Options
About this article
Cite this article as:
Wu Jie , Di Dingxin , Zhao Chen , Liu Yingyi , Chen Hongxia , Gong Yan , Zhao Xianda and Chen Honglei *, Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy, Current Cancer Drug Targets 2018; 18 (6) . https://dx.doi.org/10.2174/1568009618666171129223533
DOI https://dx.doi.org/10.2174/1568009618666171129223533 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of Glioma Specific Genes as Diagnostic and Prognostic Markers for Glioma
Current Bioinformatics Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology Patient-Specific Alpha-Particle Dosimetry
Current Radiopharmaceuticals β-Lactone Derivatives and Their Anticancer Activities: A Short Review
Current Topics in Medicinal Chemistry State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Recent Patents on Anti-Cancer Drug Discovery Multi-targeted HDAC Inhibitors as Anticancer Agents: Current Status and Future Prospective
Current Medicinal Chemistry Subject Index to Volume 2
Current Neuropharmacology Tumor Suppressive Role of MicroRNAs in Triple Negative Breast Cancer
Current Pharmaceutical Design Antioxidant Supplementation on Cancer Risk and During Cancer Therapy: An Update
Current Topics in Medicinal Chemistry Pharmacophore-based Identification of Potential Mutant Isocitrate Dehydrogenases I/2 Inhibitors: An Explorative Avenue in Cancer Drug Design
Anti-Cancer Agents in Medicinal Chemistry Epoxomicin Sensitizes Resistant Osteosarcoma Cells to TRAIL Induced Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Immunologic Diseases and Brain Tumors
Inflammation & Allergy - Drug Targets (Discontinued) Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Current Advances in Delivery of Biotherapeutics Across the Blood-Brain Barrier
Current Drug Discovery Technologies Therapeutic Application of Natural Medicine Monomers in Cancer Treatment
Current Medicinal Chemistry CASC19: An Oncogenic Long Non-coding RNA in Different Cancers
Current Pharmaceutical Design Oleuropein Mediated Targeting of Signaling Network in Cancer
Current Topics in Medicinal Chemistry Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Interplay between LncRNA/miRNA and TGF-β Signaling in the Tumorigenesis of Gynecological Cancer
Current Pharmaceutical Design An Appraisal of Current Pharmacological Perspectives of Sesamol: A Review
Mini-Reviews in Medicinal Chemistry